I know you’re happy it’s Friday, so go ahead and blast the new “Pretty In Pink” video below. It starts out slow and sexy, then picks up speed in the middle. You’ll like it!
And if you do like it, please head over to iTunes to purchase the single before April 30. Artist Ariel Aparicio is donating his proceeds of .54 cents from each purchase of the single on iTunes to the Greater New York City Affiliate of Susan G. Komen For The Cure.
Ariel wants to use his fun, violin-filled version of the Psychedelic Furs’ 1980s classic as a means for …read more

The wonder drug Herceptin is the primary treatment for HER2-positive breast cancer. The 25 -30 % of breast cancer patients with this class of tumor do not all respond to Herceptin.
However, better treatment options can be determined if breast cancer patients can be evaluated of how they would respond to Herceptin.
Research teams from Harvard and Yale Universities have been able to identify certain basal markers, growth factors and growth factor receptors in breast cancer patients that are expressed in the genes of Herceptin-resistant breast cancer patients.
The findings have been used by the team in the utilization of gene chips in profiling …read more

The good news that Herceptin® (trastuzumab) (the world’s first targeted therapy) is now available for many women with early-stage HER2-positive breast cancer, marks a significant advancement in breast cancer management.
According to Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Florida:
“…signifies the importance for women who are newly diagnosed with breast cancer to ensure the care they will receive is the best possible. Women have helped lead a revolution in the care of breast cancer, and now I think all patients should know all that they can do to help direct their care.
“…a million people are diagnosed with …read more

Increased levels of the oncogene HER-2 are associated with poor patient prognosis, enhanced metastasis (cancer spread) and resistance to chemotherapy.
Herceptin (trastuzumab) is the monoclonal antibody used in combination with certain cancer chemotherapies.
Researchers from the Northwestern University and Evanston Northwestern Healthcare found that Herceptin effectively treats breast cancer tumors that produce low or undetectable amounts of HER-2 but overexpress the growth factor heregulin (HRG), an activator of the HER-2 cancer oncoprotein. ‘
Before this finding it was believed that trastuzumab combined with cytotoxic drug therapy was effective only in HER-2—positive (or HER-2—overexpressing) breast cancer – a case that represents about 25 …read more